RxDoctor Payments Data

Meredith Kitchell, PA

Medical · Vero Beach, FLNPI 1457760084

Payments from drug & device makers

$2,039in general payments, 2019–2025

Across 89 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$298
  • Astellas Pharma US Inc$271
  • Lilly USA, LLC$233
  • Sumitomo Pharma America, Inc.$225
  • Mayne Pharma Commercial LLC$161
  • Pfizer$118
  • plus $733 from 15 others

What the payments were for

  • Food & beverage$1,94095%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,039 in reported general payments places this provider in the 70th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$18,577
Medicare patients
86
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$18,585
SynthroidLevothyroxine Sodium24$2,562
Liothyronine Sodium11$622
Escitalopram Oxalate20$451
Levothyroxine Sodium38$428
Atorvastatin Calcium15$289
Losartan Potassium23$286
Doxycycline Hyclate12$271
Omeprazole12$231
Meloxicam11$180
Fluoxetine Hcl13$159
Zolpidem Tartrate18$143
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$122
Methylprednisolone18$120
Gabapentin17$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$233$18,58520 claims
AbbVieSynthroid$298$2,56224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,031 medical providers in Florida.

Other medical in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →